These organizations might use the information in various ways but they all talk about a common need – to quickly and easily find accurate data to solution their questions. The AdisInsight platform is made to help them do just that.’.. Adis launches new system to create drug information more accessible Adis, a leading global provider of drug details, has taken a major step of progress in its quest to make expertly written drug information more accessible, with the launch of a new platform AdisInsight. The platform presents a distinctive, joined-up look at of current proof on drug treatments being developed world-wide – how well they function, how secure they are, who’s working on them, and how quickly they will be available – within a database.Clinical Significance of CALR Mutations Overall, we studied 1215 sufferers with essential thrombocythemia or primary myelofibrosis . Of these sufferers, 63.4 percent carried the JAK2 V617F mutation, 4.4 percent carried activating mutations of MPL exon 10, 23.5 percent carried mutations of CALR exon 9, and only 8.8 percent had non-e of these clonal markers. The majority of the patients without clonal markers were clustered in the subgroup of patients with essential thrombocythemia.